ANZCTR search results

This study aims to test the ability of a high protein / high soluble fibre drink to reduce the rise in blood glucose levels in people with type 2 diabets following a high carbohydrate meal when taken 15 minutes before that meal.

The main aim of the study is to work out the safest dose of PENAO to give to patients. PENAO is an organoarsenic which means it is related to arsenic. There are other drugs in this class which are used to treat different forms of cancer. In this research study patients will be given a new drug, PENAO, for the first time. This drug has been previously safely tested in animals but has not been tested before in humans. Because of this, it is unknown what the most effective and safe dosage level should be. Secondly, the study aims to monitor patients to collect more information about how the drug is broken down by the body and do scans to observe whether the drug has an effect on tumours. To date, this drug has been shown to slow or stop the growth of many different types of tumours when grown in mice. PENAO is an experimental drug. This means that it is not an approved treatment for cancer in Australia or other parts of the world. This study drug was developed by a group of researchers at the University of NSW as an anti-cancer agent. This research and the clinical study are funded by the Cancer Institute of NSW.

Ageing is associated with a physiological reduction of appetite and energy intake, which has been called the “anorexia of ageing”. Dietary supplementation with liquid protein preparations is now used frequently to increase energy and protein intake in older adults in both institutionalized and community-dwelling populations. Although the latter would appear a logical approach, evidence for success of increased energy intake in older individuals is limited. There is consensus that nutrient stimuli in the gastrointestinal (GI) tract, especially in the small intestine, play a major role in the regulation of appetite and energy intake via modulation of GI motility and hormone release. Increasing our knowledge of how protein affects GI motility and hormone release is of increasing relevance in healthy and undernourished older individuals. In addition to the effects of healthy ageing, there is evidence of differences between undernourished and well-nourished older people, which may potentially result from being undernourished and/or contribute to the undernourished state. Urgent investigation is warranted to determine the effects of oral protein intake, so that protein can be incorporated into their diet to assist in sparing muscle mass without reducing their appetite. The study aims to characterise in older individuals, the effect of undernutrition on energy intake, appetite, antropyloroduodenal motility, plasma concentrations of amino acids, hormones (i.e. CCK, PYY, ghrelin, GLP-1, GIP, glucagon and insulin) and glucose after intraduodenal protein infusion.

Ageing is associated with a physiological reduction of appetite and energy intake, which has been called the “anorexia of ageing”. Dietary supplementation with liquid protein preparations is now used frequently to increase energy and protein intake in older adults in both institutionalized and community-dwelling populations. Although the latter would appear a logical approach, evidence for success of increased energy intake in older individuals is limited. There is consensus that nutrient stimuli in the gastrointestinal (GI) tract, especially in the small intestine, play a major role in the regulation of appetite and energy intake via modulation of GI motility and hormone release. Increasing our knowledge of how protein affects GI motility and hormone release is of increasing relevance in older individuals. Urgent investigation is warranted to determine the optimal load of protein that can be incorporated into their diet to assist in sparing muscle mass without reducing their appetite. The study aims to characterise in healthy older individuals, the effect of different intraduodenal protein loads on energy intake, appetite, antropyloroduodenal motility, plasma concentrations of amino acids, gut hormones and glucose, and to determine the relationship between the suppression of appetite and energy intake by protein with ‘small intestinal’ mechanisms.

Since alcohol consumption is linked to more than 60 different medical conditions and is the most common preventable risk factor associated with injuries in Australia, interventions that can reduce these harms are needed. This study is designed to determine whether a computer-based brief alcohol intervention reduces hazardous drinking among hospital outpatients. If effective, the intervention could be implemented nationally as part of routine service delivery.

Rheumatoid Arthritis (RA) is a chronic disease which when left untreated leads to long term joint damage, loss of function and a reduced life expectancy. There is evidence that by treating RA early with combination therapies the damage to the joints may be much less and function preserved. Following on from this observation, many rheumatologists think aiming for a specific end point to prevent progressive joint damage should be introduced. However, new TNF agents such as Adalimumab seem to protect against damage more than do conventional therapies even when signs and symptoms of arthritis are equally controlled. The explanation for this is unclear and needs to be explored further.

Although distal radius fractures commonly occur, factors that affect treatment outcomes have not been well defined. There is a gap in our current knowledge regarding how long a wrist should be immobilised in a cast following surgical repair. The aim of this investigation is to compare participants following surgical repair of their distal radius fracture and immobilised in a cast for either one, three or six weeks. The hypothesis for this investigation is that three or six weeks of immobilisation is not superior to one week of immobilisation for participants following surgery for acute distal radius fracture for any of the recorded outcomes when measured over a six month period from the date of surgery. The information gained from this investigation will enable us to improve the management of distal radius fractures following surgical repair in the future. It is known from previous investigations that moving the fractured area as early as one to two days following surgical repair of a fracture is safe. Previous investigations also tell us that immobilisation periods ranging from less than one week up to six weeks have their advantages and disadvantages. This investigation aims to compare the immobilisation periods of one, three and six weeks so we can determine the best management for participants following a surgical repair for distal radius fracture.

Who is it for? You can join this study if you have metastatic colorectal cancer and have either a KRAS wild type or KRAS G13D mutation Trial details: Patients that pass all screening assessments, including CT scan and blood test will randomly divided into two groups. One group wiil receive cetuximab alone ( Arm A) and the other group will receive cetuximab in combination with irinotecan ( Arm B). In both groups, the chemotherapy is given intravenously. Cetuximab is administered weekly to both groups and patients in Arm B will receive irinotecan every 14 days. The study aims to evaluate the response to the different therapy regimens, by looking at the response on CT scans, survival rates and quality of life.

Measurement of neuroprostane and isofuran levels in plasma and CSF may give prognostic information in traumatic brain injury. The study aims are: 1) To establish the correlation between plasma and CSF levels of these markers in a population of severely brain injured patients and 2) To establish correlation between neuroprostane and isofuran levels and outcome as measured by glasgow outcome score and anterograde amnesia score.

This project aims to (1) assess the effectiveness of a coaching intervention (C) in increasing adherence to CPAP compared with an enhanced education or treatment as usual (TAU) intervention; (2) to identify individuals with low self-efficacy scores who are at risk of stopping treatment and (3) to examine the role of mood, quality of life and well-being in the treatment response. The hypothesis is that the C intervention will increase uptake and adherence to CPAP and will improve low baseline self-efficacy scores as individuals feel they can perceive themselves using CPAP effectively. By using CPAP on a nightly basis for most of the night, mood and well-being, sleepiness and sleep related quality of life and self-efficacy will also be improved. A total of 60 individuals diagnosed with OSA will be recruited into the study on the basis of being naive to CPAP treatment and having low self-efficacy scores (<4). Participants will be randomised to either the current treatment as usual group (TAU) which consists of psycho-education and mask fitting (1.5 - 2 hours) before the CPAP titration night or a coaching group (C). The C group will undergo the psycho-education and mask fitting but will also undertake 4 individual coaching sessions at baseline (3 face-to-face session and 1 by telephone). All participants will be asked attend 4 CPAP data usage download sessions and to complete questionnaires at baseline, 1 week after starting CPAP, 1 month after starting CPAP, 12 weeks after starting CPAP and 3 months after study end. All participants will receive a CPAP machine and tubing free of charge for the duration of the study. Past CPAP research has found that self-efficacy predicts CPAP adherence, and as SF/CBC has been found to enhance self-efficacy and goal attainment and adherence, thus advancing knowledge and practice in CPAP and contributing to the broader emerging area of health coaching.